Overall, leveraging the multifaceted neurovascular protective effects of endogenous SDF‐1α/CXCR4 signaling presents a promising avenue for developing stroke therapies to maintain BBB integrity after ischemia. The gene discussed is CXCL12; the disease is stroke disorder.